Koers Mabvax Therapeutics Holdings Inc Nasdaq
Aandelen
US87959M2089
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2016 | 148K 136K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,28 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,66 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,51 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 433K | Nettoschuld 2017 | 2,48 mln. 2,29 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,77% | 115 mld. | |
+12,85% | 107 mld. | |
-13,55% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-6,59% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,86% | 14,26 mld. | |
+33,05% | 12,37 mld. | |
-27,97% | 8,28 mld. |
- Beurs
- Aandelen
- Koers MBVXQ
- Koers